Literature DB >> 18662771

Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.

Greg Vilk1, Jane E Weber, Jacob P Turowec, James S Duncan, Chenggang Wu, D Richard Derksen, Piotr Zien, Stefania Sarno, Arianna Donella-Deana, Gilles Lajoie, Lorenzo A Pinna, Shawn S C Li, David W Litchfield.   

Abstract

Protein kinase CK2 exhibits oncogenic activity in mice and is over-expressed in a number of tumors or leukemic cells. On the basis of its amino acid sequence and a wealth of experimental information, CK2 has traditionally been classified as a protein serine/threonine kinase. In contrast to this traditional view of CK2, recent evidence has shown that CK2 can also phosphorylate tyrosine residues under some circumstances in vitro and in yeast. In this study, we provide definitive evidence demonstrating that CK2 also exhibits tyrosine kinase activity in mammalian cells. Tyrosine phosphorylation of CK2 in cells and in CK2 immunoprecipitates is dependent on CK2 activity and is inhibited by the CK2 selective inhibitor 4,5,6,7-tetrabromobenzotriazole. Examination of phosphotyrosine profiles in cells reveals a number of proteins, including CK2 itself, which exhibit increased tyrosine phosphorylation when CK2 levels are increased. Peptide arrays to evaluate the specificity determinants for tyrosine phosphorylation by CK2 reveal that its specificity for tyrosine phosphorylation is distinct from its specificity for serine/threonine phosphorylation. Of particular note is the requirement for an aspartic acid immediately C-terminal to the phosphorylatable tyrosine residue. Collectively, these data provide conclusive evidence that CK2 catalyzes the phosphorylation of tyrosine residues in mammalian cells, a finding that adds a new level of complexity to the challenge of elucidating its cellular functions. Furthermore, these results raise the possibility that increased CK2 levels that frequently accompany transformation may contribute to the increased tyrosine phosphorylation that occurs in transformed cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662771     DOI: 10.1016/j.cellsig.2008.07.002

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  23 in total

1.  Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling.

Authors:  Beth Bragdon; Shayamala Thinakaran; Oleksandra Moseychuk; Daniel King; Kira Young; David W Litchfield; Nils O Petersen; Anja Nohe
Journal:  Biophys J       Date:  2010-08-04       Impact factor: 4.033

2.  Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Authors:  Christian Borgo; Luca Cesaro; Valentina Salizzato; Maria Ruzzene; Maria Lina Massimino; Lorenzo A Pinna; Arianna Donella-Deana
Journal:  Mol Oncol       Date:  2013-08-22       Impact factor: 6.603

3.  Protein kinase CK2-mediated phosphorylation of HDAC2 regulates co-repressor formation, deacetylase activity and acetylation of HDAC2 by cigarette smoke and aldehydes.

Authors:  David Adenuga; Irfan Rahman
Journal:  Arch Biochem Biophys       Date:  2010-04-11       Impact factor: 4.013

4.  Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum.

Authors:  Lev Solyakov; Jean Halbert; Mahmood M Alam; Jean-Philippe Semblat; Dominique Dorin-Semblat; Luc Reininger; Andrew R Bottrill; Sharad Mistry; Abdirhaman Abdi; Clare Fennell; Zoe Holland; Claudia Demarta; Yvan Bouza; Audrey Sicard; Marie-Paule Nivez; Sylvain Eschenlauer; Tenzing Lama; Divya Catherine Thomas; Pushkar Sharma; Shruti Agarwal; Selina Kern; Gabriele Pradel; Michele Graciotti; Andrew B Tobin; Christian Doerig
Journal:  Nat Commun       Date:  2011-11-29       Impact factor: 14.919

5.  Identification of a novel function of the clathrin-coated structure at the plasma membrane in facilitating GM-CSF receptor-mediated activation of JAK2.

Authors:  Ping-Hung Chen; Fan-Ching Chien; Sue-Ping Lee; Woan-Eng Chan; I-Hsuan Lin; Chun-Shan Liu; Fang-Jen Lee; Jiann-Shiun Lai; Peilin Chen; Hsin-Fang Yang-Yen; Jeffrey Jong-Young Yen
Journal:  Cell Cycle       Date:  2012-08-30       Impact factor: 4.534

6.  A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.

Authors:  Ying Zheng; Hongwei Qin; Stuart J Frank; Luqin Deng; David W Litchfield; Ayalew Tefferi; Animesh Pardanani; Fang-Tsyr Lin; Jingzhi Li; Bingdong Sha; Etty N Benveniste
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

7.  Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics.

Authors:  Laszlo Gyenis; Daniel Menyhart; Edward S Cruise; Kristina Jurcic; Scott E Roffey; Darren B Chai; Flaviu Trifoi; Sam R Fess; Paul J Desormeaux; Teresa Núñez de Villavicencio Díaz; Adam J Rabalski; Stephanie A Zukowski; Jacob P Turowec; Paula Pittock; Gilles Lajoie; David W Litchfield
Journal:  Front Mol Biosci       Date:  2022-06-09

8.  Casein kinase 2 associates with the yeast chromatin reassembly factor Spt2/Sin1 to regulate its function in the repression of spurious transcription.

Authors:  Wajid Bhat; Geneviève Boutin; Anne Rufiange; Amine Nourani
Journal:  Mol Cell Biol       Date:  2013-08-26       Impact factor: 4.272

9.  Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.

Authors:  Laszlo Gyenis; James S Duncan; Jacob P Turowec; Maria Bretner; David W Litchfield
Journal:  J Proteome Res       Date:  2011-10-13       Impact factor: 4.466

Review 10.  CK2 inhibition protects white matter from ischemic injury.

Authors:  Selva Baltan; Chinthasagar Bastian; John Quinn; Danielle Aquila; Andrew McCray; Sylvain Brunet
Journal:  Neurosci Lett       Date:  2018-08-17       Impact factor: 3.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.